

B!
filed June 30, 1994, which issued as U.S. Patent 5,538,982 on July 23, 1996; which is a divisional of Application No. 07/946,635, filed on September 18, 1992, which issued as U.S. Patent 5,360,820 on November 1, 1994; the entire contents of which are hereby incorporated by reference and for which priority is claimed under 35 U.S.C. § 120; and this application claims priority of Application Nos. 91 20172.3; 92 02839.8; and 92 04151.6 filed in Great Britain on September 20, 1991; February 11, 1992; and February 27, 1992, respectively, under 35 U.S.C. § 119.--

REMARKS

The specification has been amended to update the status of the parent application, which is now patented.

Applicants respectfully request that an interference be declared under the provisions of 35 U.S.C. § 135 between the above-identified Application No. 09/986,679 and U.S. Patent 5,576,317 (hereinafter referred to as the Pfizer '317 patent), which issued on November 19, 1996, and is assigned to Pfizer Inc. of New York, New York.

Applicants herein present the following facts in compliance with 37 C.F.R. § 1.607. The following paragraph numbers correspond to the paragraph numbers of § 1.607(a).

- (1) Applicants request an interference with U.S. Patent 5,576,317.
- (2) The Proposed Counts for the interference are as follows:

PROPOSED COUNT 1

A pharmaceutical composition for the treatment or prevention of emesis comprising a 5HT₃ receptor-antagonist, an NK-1 receptor antagonist and a pharmaceutically acceptable carrier.

OR

A method of treating or preventing emesis in a mammal, comprising administering to said mammal an anti-emetic effective amount of a pharmaceutical composition comprising a 5HT₃ receptor antagonist, an NK-1 receptor antagonist and a pharmaceutically acceptable carrier.

OR

A method of treating or preventing emesis in a mammal, comprising administering to said mammal a 5HT₃ receptor antagonist and an NK-1 receptor antagonist in amounts that render the combination of such two active agents effective in the treatment or prevention of such disorder.

PROPOSED COUNT 2

A pharmaceutical composition for the treatment or prevention of emesis comprising a 5HT₃ receptor-antagonist selected from the group consisting of ondansetron, tropisetron, granisetron and metoclopramide, an NK-1 receptor antagonist and a pharmaceutically acceptable carrier.

OR

A method of treating or preventing emesis in a mammal, comprising administering to said mammal an anti-emetic effective amount of a

pharmaceutical composition comprising an NK-1 receptor antagonist and either ondansetron, tropisetron, granisetron and metoclopramide.

OR

A method of treating or preventing emesis in a mammal, comprising administering to said mammal a 5HT₃ receptor antagonist selected from the group consisting of ondansetron, tropisetron, granisetron and metoclopramide and an NK-1 receptor antagonist in amounts that render the combination of such two active agents effective in the treatment or prevention of such disorder.

(3) Claim 1 of the Pfizer '317 patent corresponds exactly to the first alternative of Proposed Count 1, claim 4 of the Pfizer '317 patent corresponds exactly to the second alternative of Proposed Count 1, and claim 7 of the Pfizer '317 patent corresponds exactly to the third alternative of Proposed Count 1. Claims 3, 5, 8, 9, 10, 12, 13 and 14 of the '317 patent also correspond to Proposed Count 1.

Claims 2, 6 and 11 of the '317 patent correspond to proposed Count 2.

(4) Claim 11 of the present '679 application corresponds exactly to the first alternative of Proposed Count 1. Claim 14 of the present '679 application corresponds exactly to the second alternative of Proposed Count 1. Claim 16 of the present '679 application corresponds exactly to the third alternative of Proposed Count 1.

Claims 3, 12, 15 and 19 of the '679 application correspond to Proposed Count 2.

It is to be noted that claim 1 in the present '679 application corresponds exactly to claim 18 of parent Application No. 08/706,836, which was filed on September 3, 1996. Claim 1 of the present application (and therefore claim 18 of the parent '836 application) corresponds substantially to claim 4 of the Pfizer '317 patent except that present claim 1 recites that the NK₁ antagonist is used in combination with a systemic anti-inflammatory corticosteroid or 5HT₃ antagonist. Thus, although claim 1 of the present '679 application varies slightly in wording from claim 4 of the Pfizer '317 patent, these claims have substantial overlap and are directed to the same invention. Therefore, claim 1 of the present '679 application corresponds to Proposed Count 1.

Claim 3 of the present '679 application, claim 20 in the parent '836 application and claim 6 of the Pfizer '317 patent (which all correspond to Proposed Count 2) substantially overlap since two of the recited NK-1 receptor antagonists (i.e., ondansetron and granisetron) are identical. Therefore, these claims are directed to the same invention and correspond to Proposed Count 2.

Claims 2 and 4-10 in the present '679 application correspond exactly to claims 19 and 21-27, respectively, in the parent '836 application, the latter claims having been submitted to the USPTO on

September 3, 1996, prior to the issuance of the Pfizer '317 patent on November 19, 1996.

(5) All of the terms which appear in any application claim corresponding to Proposed Counts 1 and 2 are present in the disclosure of the '679 application and also in the parent '836 application. Appendix A, attached hereto, applies the terms of claims 1 and 3 (corresponding to Proposed Counts 1 and 2) to the disclosure in the present '679 application as well as the disclosure in the parent '836 application.

(6) Applicant submits that the claims of the present '679 application, which correspond to Proposed Counts 1 and 2, do not violate 35 U.S.C. § 135(b). 35 U.S.C. § 135(b) provides in relevant part:

"A claim which is the same as, or for the same or substantially the same subject matter as, a claim of an issued patent may not be made in any application unless such a claim is made prior to one year from the date on which the patent was granted . . ." (*emphasis added*).

This provision requires an applicant to present "conflicting claims" prior to one year from the date of patent issuance.

The Pfizer '317 patent issued on November 19, 1996. The applicant herein presented claims substantially the same as the claims in the Pfizer patent in parent Application No. 08/706,836 on September 3, 1996. The applicant subsequently cancelled the "conflicting claims" from the application during *ex parte* prosecution on May 22, 1997 (after issuance

of the '317 patent). However, the original presentation of the "conflicting claims" occurred during the pendency of the Pfizer application and before the Pfizer '317 patent issued. These claims were also present in the '836 application after the Pfizer '317 patent issued. Applicant has reintroduced these previously cancelled "conflicting claims" in the present application.

Such reintroduction of claims is permitted according to the decision in *Tezuka, et al. v. Wilson, et al.*, 224 USPQ 1030 (Bd. Pat. App.s Int. 1984), which interprets the relevant statutory provision. Pursuant to *Tezuka*, Applicant is entitled to reintroduce the "conflicting claims" in the present divisional application even though the divisional application was filed on November 5, 2001, more than one year after the issuance of the Pfizer patent on November 19, 1996.

In the *Tezuka* case, the Board interpreted the words "prior to" in 35 U.S.C. § 135(b). The issue before the Board was whether Wilson had presented claims in his application for the same or substantially the same subject matter as *Tezuka's* patent claims 1 to 3 prior to one year from the date on which the *Tezuka* patent was granted as required by 35 U.S.C. § 135(b). Wilson's parent application, filed on September 6, 1977, contained original claims 24-30, directed to a cement-forming liquid for use as a component of a poly(carboxylate) cement. These claims were cancelled on July 21, 1978, and were not reasserted in the parent application. These claims were then presented in Wilson's involved application filed on June 14, 1979, which was more than one

year after the issuance of the Tezuka patent on May 16, 1978. Claim 32 was also presented at this time as a substantial copy of Tezuka's patent claim 1 in order to provoke an interference with Wilson. Tezuka argued that Wilson had not claimed the same or substantially the same subject matter as that claimed in the Tezuka patent within the time required by the statute. The Board held that Wilson had claimed substantially the same subject matter as that of Tezuka's claims 1 to 3 prior to one year from the date on which the Tezuka patent was granted. The Board found that "the words 'prior to' in 35 U.S.C. § 135(b) point to a critical date prior to which the copier had to be claiming the invention. It does not matter whether the claims are subsequently cancelled either before or after the issuance of the patent." (*id.*, at 1036) (*emphasis added*).

Like Wilson in the Tezuka case, the Applicant herein introduced the "conflicting claims" in the parent '836 application and subsequently cancelled them. In Tezuka, Wilson introduced the conflicting claims in an application that was filed one year after the issuance of the Tezuka patent. Likewise, the "conflicting claims" in the present '679 application were originally introduced in a parent application that was pending during the pendency of the Pfizer '317 patent.

Following the reasoning set forth in Tezuka, Applicant should be allowed to reintroduce the "conflicting claims" in the present divisional application and request an interference pursuant to 37 C.F.R.

§ 1.607, even though this divisional application was filed more than one year after the issuance of the Pfizer '317 patent.

Applicants are entitled to the benefit of all prior U.S. applications for proposed Counts 1 and 2, including Application No. 08/706,836, filed on September 3, 1996, which issued as U.S. Patent 6,326,383 B1 on December 4, 2001, which is a continuation of Application No. 08/579,294, filed on December 27, 1995, which issued as U.S. Patent 5,798,363 on August 25, 1998, which is a continuation of Application No. 08/269,079, filed June 30, 1994, which issued as U.S. Patent 5,538,982 on July 23, 1996, which is a divisional of Application No. 07/946,635, filed on September 18, 1992, which issued as U.S. Patent 5,360,820 on November 1, 1994.

Applicants are also entitled to the filing date of U.K. application 92 04151.6 for proposed Counts 1 and 2, which was filed on February 27, 1992. A copy of this application is attached hereto.

The Examiner is requested to refer in particular to the first full paragraph on page 14 of the U.K. application which reads as follows:

The tachykinin antagonists may, if desired, be administered [in] combination with one or more other therapeutic agents and formulated for administration by any convenient route in a conventional manner. Appropriate doses will be readily appreciated by those skilled in the art. For example, the tachykinin antagonists may be administered in combination with a systemic anti-inflammatory corticosteroid such as methyl prednisolone or dexamethasone, or a 5HT₃ antagonist such as ondansetron, granisetron or metoclopramide.

For the foregoing reasons, Applicant submits that all of the provisions of 37 C.F.R. § 1.607 have been met, and respectfully requests


that an interference be declared between the present '679 application and the Pfizer '317 patent.

Should there be any outstanding matters that need to be resolved in the present application, the Examiner is respectfully requested to contact the undersigned at the telephone number shown below.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By 
Gerald M. Murphy, Jr. (Reg. No 28,977)
Raymond C. Stewart (Reg. No. 21,066)

P.O. Box 747
Falls Church, VA 22040-0747
(703) 205-8000

RCS/GMM/las/kdm

Attachments:

Marked-up Version Showing Changes Made
Appendix A
U.K. Application No. 92 04151.6

MARKED-UP VERSION SHOWING CHANGES MADE

In the Specification:

The first paragraph on page 1 of the specification has been amended as follows:

This application is a [☐ continuation ☒ divisional ☐ continuation-in-part] of [co-pending] Application No. 08/706,836, filed on September 3, 1996, which issued as U.S. Patent 6,326,383 B1 on December 4, 2001, which is a continuation of Application No. 08/579,294, filed on December 27, 1995, [now] which issued as U.S. Patent 5,798,363 on August 25, 1998, which is a continuation of Application No. 08/269,079, filed June 30, 1994, [now] which issued as U.S. Patent 5,538,982 on July 23, 1996; which is a divisional of Application No. 07/946,635, filed on September 18, 1992, [now] which issued as U.S. Patent 5,360,820 on November 1, 1994; the entire contents of which are hereby incorporated by reference and for which priority is claimed under 35 U.S.C. § 120; and this application claims priority of Application Nos. 91 20172.3; 92 02839.8; and 92 04151.6 filed in Great Britain on September 20, 1991; February 11, 1992; and February 27, 1992, respectively, under 35 U.S.C. § 119.--

Appendix A

Claims in Application No. 08/706,836 (Parent Appln.)	Claims in Application No. 09/986,679 (Present Appln.)	Disclosure in the '836 and '679 Applications which supports the corresponding claims.
18	1 (Proposed Count 1)	Page 1, lines 23-27; Page 2, lines 23-26; Page 22, lines 5-8; and Page 28, lines 18-25
20	3 (Proposed Count 2)	Page 22, lines 5-8; Page 28, lines 22-25



Europäisches
Patentamt

European
Patent Office

Office européen
des brevets

Bescheinigung

Certificate

Attestation

Die angehefteten Unterla-
gen stimmen mit den in
den Akten befindlichen
Unterlagen der unten be-
zeichneten europäischen
Patentanmeldung überein
(Regel 94(4) EPÜ).

The attached is a true copy
of documents contained in
the European patent appli-
cation indicated below
(Rule 94(4) EPC).

Les documents ci-annexés
sont conformes aux
documents figurant dans
le dossier de la demande
de brevet dont le numéro
est indiqué ci-dessous
(règle 94(4) CBE).

Patentanmeldung Nr. Patent application No. Demande de brevet n°

92202831.1

München
Munich
Munich, 05/06/97

Der Präsident des Europäischen Patentamts:
Im Auftrag.

For the President of the European Patent Office.

Le Président de l'Office européen des brevets
p.o.

H. Kuebart

Helga Kuebart

The
Patent
Office

The Patent Office
Cardiff Road
Newport
Gwent
NP9 1RH


I, the undersigned, being an officer duly authorised in accordance with Section 62(3) of the Patents and Designs Act 1907, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the Patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or the inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.


Signed



Dated 3rd September 1992

-2MAY 192H002892

27 FEB 1992



/JV/CH181

9274151.6

type, or write in dark ink
CAPITAL letters. A prescribed
payable for a request for grant
stent. For details, please
at the Patent Office (telephone
38 4700).

The
Patent
Office

Request for grant of a Patent Form 1/77

Patents Act 1977

'6 of the Patents Rules 1990
main rule governing the
letion and filing of this form.

1 Title of invention

MEDICAMENTS

1 Please give the title of
the invention

2 Applicant's details

☐ First or only applicant

2a If you are applying as a corporate body please give:

Corporate name
GLAXO GROUP LIMITED

Country (and State of incorporation, if appropriate)

GREAT BRITAIN

2b If you are applying as an individual or one of a partnership please give in full:

Surname

Forenames

2c In all cases, please give the following details:

Address
GLAXO HOUSE
BERKELEY AVENUE
GREENFORD
MIDDLESEX

UK postcode UB6 ONN
(if applicable)

Country GREAT BRITAIN

ADP number
(if known)

5969647001 P.A.

not give trading styles, for
ple, 'Trading as XYZ company',
ality or former names, for
ple, 'formerly (known as) ABC
is these are not required.

er an application for a Patent has
filed, the Comptroller of the
ent Office will consider whether
lication or communication of the
ention should be prohibited or
stricted under Section 22 of the
ents Act 1977 and will inform
applicant if such prohibition or
striction is necessary. Applicants
ident in the United Kingdom are
to reminded that under Section 23,
lications may not be filed
road without written permission
less an application has been filed
t less than 6 weeks previously in
e United Kingdom for a patent for
e same invention and either no
ection prohibiting publication or
ommunication has been given, or
y such direction revoked.

1e and 2f:
If there are further applicants
they provide details on a separate
sheet of paper.

☐ Second applicant (if any)

2d If you are applying as a corporate body please give:

Corporate name

Country (and State of incorporation, if appropriate)

2e If you are applying as an individual or one of a partnership please give in full:

Surname

Forenames

2f In all cases, please give the following details:

Address

UK postcode
(if applicable)

Country

ADP number 00473587001
(if known)

If an address for service in the United
Kingdom must be supplied.

Please mark correct box

3 Address for service details

3a Have you appointed an agent to deal with your application?

Yes ☒ No ☐ ➔ go to 3b

↓
Please give details below

Agent's name

C. L. BREWER / S. R. JAMES / W. A. FILLER

Agent's address

C/O GLAXO HOLDINGS P.L.C.

GLAXO HOUSE

BERKELEY AVENUE

GREENFORD, MIDDLESEX

Postcode UB6 0NN

Agent's ADP
number

5841499002

3b:
If you have appointed an agent,
all correspondence concerning
your application will be sent to
the agent's United Kingdom
address.

3b If you have not appointed an agent please give a name and address in the United
Kingdom to which all correspondence will be sent:

Name

Address

Postcode
ADP number
(if known)

Daytime telephone
number (if available)

CLB/JV/CH181

Please mark correct box

5 Are you claiming that this application be treated as having been filed on the date
of filing of an earlier application?

Yes ☐ No ☒ ➔ *go to 6*

please give details below

☐ number of earlier application or patent number

☐ filing date

(day month year)

☐ and the Section of the Patents Act 1977 under which you are claiming:

15(4) (Divisional) ☐ 8(3) ☐ 12(6) ☐ 37(4) ☐

6 If you are declaring priority from previous application(s), please give:

If you are declaring priority from a PCT Application please enter 'PCT' as the country and enter the country code (for example, GB) as part of the application number.

ase give the date in all number
mat, for example, 31/05/90 for 31
ay 1990.

Country of filing	Priority application number (if known)	Filing date (day, month, year)

answer must be 'No' if:
applicant is not an inventor
or is an inventor who is not
an applicant, or
applicant is a corporate
body.

se supply duplicates of
claim(s), abstract, description
and drawing(s).

use mark correct box(es)

or your appointed agent
Rule 90 of the Patents
Act 1990) must sign this
statement.

Please sign here →

Completed fee sheet should
accompany the fee.

7 Inventorship

7 Are you (the applicant or applicants) the sole inventor or the joint inventor?

Please mark the correct box

Yes ☐ No ☒ →

A statement of Inventorship on Patents Form 7/77 will need to be filed (see Rule 15).

8 Checklist

8a Please fill in the number of sheets for each of the following types of document contained in this application.

Continuation sheets for this Patents Form 1/77

Claim(s)

Description

14

Abstract

Drawing(s)

8b Which of the following documents also accompanies the application?

Priority documents (please state how many)

Translation(s) of Priority documents (please state how many)

Patents Form 7/77 - Statement of Inventorship and Right to Grant (please state how many)

Patents Form 9/77 - Preliminary Examination/Search

Patents Form 10/77 - Request for Substantive Examination

9 Request

I/We request the grant of a patent on the basis of this application.

Signed

Date 27/02/1992

C. L. Brewer Agent for the Applicant (day month year)

Please return the completed form, attachments and duplicates where requested, together with the prescribed fee to:

☐ The Comptroller
The Patent Office
Cardiff Road
NEWPORT
Gwent
NP9 1RH

The Comptroller
The Patent Office
25 Southampton Buildings
London
WC2A 1AY

CH181

MEDICAMENTS

The present invention relates to the use of tachykinin antagonists, including substance P and other neurokinin antagonists, in the treatment of emesis.

Tachykinin antagonists are known to be useful in the treatment of a variety of disorders including pain, inflammatory diseases, allergic disorders, CNS disorders, skin disorders, cough and gastrointestinal disorders such as ulcerative colitis and Crohn's disease.

It has now been found that tachykinin antagonists, including substance P and other neurokinin antagonists, are useful in the treatment of emesis.

The invention accordingly provides, in a first aspect, the novel use of tachykinin antagonists, including substance P and other neurokinin antagonists, in the treatment of emesis.

There is also provided as a further aspect of the invention the use of tachykinin antagonists, including substance P and other neurokinin antagonists, in the preparation of a medicament for use in the treatment of emesis.

In an alternative or further aspect there is provided a method for the treatment of a mammal, including man, suffering from or susceptible to emesis, comprising administration of an effective amount of a tachykinin antagonist, including substance P and other neurokinin antagonists.

It will be appreciated that reference to treatment is intended to include prophylaxis as well as the alleviation of established symptoms.

Tachykinin antagonists, including substance P and other neurokinin antagonists, have been shown to have anti-emetic activity as indicated by for example their ability to inhibit cisplatin-induced emesis in the ferret.

The treatment of emesis mentioned hereinbefore includes the treatment of nausea, retching and vomiting. Emesis includes acute emesis, delayed emesis and anticipatory emesis. Tachykinin

CH181

CH181

Part

antagonists, including substance P and other neurokinin antagonists, are useful in the treatment of emesis however induced. For example, emesis may be induced by drugs such as cancer chemotherapeutic agents such as alkylating agents, e.g. cyclophosphamide, carmustine, lomustine and chlorambucil; cytotoxic antibiotics, e.g. dactinomycin, doxorubicin, mitomycin-C and bleomycin; anti-metabolites, e.g. cytarabine, methotrexate and 5-fluorouracil; vinca alkaloids, e.g. etoposide, vinblastine and vincristine; and others such as cisplatin, dacarbazine, procarbazine and hydroxyurea; and combinations thereof; radiation sickness; radiation therapy, e.g. irradiation of the thorax or abdomen, such as in the treatment of cancer; poisons; toxins such as toxins caused by metabolic disorders or by infection, e.g. gastritis; pregnancy; vestibular disorders, such as motion sickness; post-operative sickness; gastrointestinal obstruction; reduced gastrointestinal motility; visceral pain, e.g. myocardial infarction or peritonitis; migraine; increased intracranial pressure; and decreased intracranial pressure (e.g. altitude sickness).

Tachykinin antagonists acting at NK_1 receptors have been found to be particularly useful in the treatment of emesis.

In a preferred aspect therefore the invention provides the use of an NK_1 receptor antagonist in the treatment of emesis.

Specific tachykinin antagonists for use in the present invention include those generically and specifically disclosed in the following patent specifications which disclosures are incorporated herein by reference:-

EP 0327009;

EP 0333174;

WO 91/12266;

EP 0284942;

GB 2216529;

US 4839465; and

WO 91/02745

CH181

Particularly preferred are the tachykinin antagonists disclosed in :-


EP 0360390 in particular:

N-[N¹-[L-pyroglutamyl-L-alanyl-L-aspartyl-L-prolyl-L-asparaginyl-L-lysyl-L-phenylalanyl-L-tyrosyl]-4-methyl-1-oxo-2S-(6-oxo-5S-1, 7-diazaspiro[4. 4]non-7-yl)pentyl]-L-tryptophanamide and

N-[N¹-[L-arginyl-L-prolyl-L-lysyl-L-prolyl-L-glutamyl-L-glutamyl-L-phenylalanyl-L-phenylalanyl]-4-methyl-1-oxo-2S-(6-oxo-5S-1,7-diazaspiro[4. 4]nonan-7-yl)-pentyl]-L-tryptophanamide;

WO 90/05525

WO 90/05729 i.e. quinuclidine derivatives of the formulae:



including the pharmaceutically acceptable salts thereof; wherein Ar is thienyl, phenyl, fluorophenyl, chlorophenyl or bromophenyl; R is hydrogen or alkyl having from one to four carbon atoms; R¹ is cycloalkyl having from five to seven carbon atoms, norbornyl, pyrrolyl, 2,3-dihydrobenzofuranyl, thienyl, alkoxythienyl having from one to three carbon atoms in the alkoxy moiety, pyridyl, hydroxypyridyl, quinoliny, indolyl, naphthyl, alkoxy naphthyl having from one to three carbon atoms in the alkoxy moiety, biphenyl 2,3-methylenedioxyphenyl, or phenyl optionally substituted with up to two substituents selected from cyano, nitro, amino, N-monoalkylamino having from one to three carbon atoms in the alkyl moiety, fluorine, chlorine, bromine, trifluoromethyl, alkyl having from one to three carbons, alkoxy having from one to three carbon atoms, allyloxy,


CH181

CH181

hydroxy, carboxy, alkoxycarbonylbenzyloxy having from one to three carbon atoms in the alkoxy moiety, carboxamido or N, N-dialkylcarboxamido having from one to three carbon atoms in the alkyl moiety; and R¹¹ is branched chain alkyl having from three to four carbon atoms, branched chain alkenyl having from five to six carbon atoms, cycloalkyl having from five to seven carbon atoms, furyl, thienyl, pyridyl, indolyl, biphenyl, or phenyl optionally substituted with up to two substituents selected from fluorine, chlorine, bromine, trifluoromethyl, alkyl having from one to three carbon atoms, alkoxy having from one to three carbon atoms, carboxy, alkoxycarbonyl having from one to three carbon atoms in the alkoxy moiety or benzyloxycarbonyl, with the proviso that said R¹¹ is always other than unsubstituted phenyl, fluorophenyl, chlorophenyl, bromophenyl or alkylphenyl when said R¹ is unsubstituted phenyl, pyrrolyl or thienyl and Ar is other than thienyl;

for example cis-3-[(2-methoxyphenyl)methylamino]-2-benzhydryl-quinuclidine;


WO 91/18899 i.e. compounds of the formula:



wherein R¹ is hydrogen or (C₁-C₆)alkyl; R² is phenyl, pyridyl, thienyl or furyl, and R² may optionally be substituted with from one to three substituents independently selected from (C₁-C₄)alkyl, (C₁-C₄)alkoxy, chloro, fluoro, bromo, iodo and trifluoromethyl; R³ is phenyl, naphthyl, pyridyl, thienyl or furyl, and R³ may optionally be substituted with one to three substituents independently selected from (C₁-C₄)alkyl, (C₁-C₄)alkoxy, chloro, fluoro, bromo, iodo and trifluoromethyl; and the pharmaceutically acceptable salts of such compounds;

EP 0429366 i.e. isoindoline derivatives of the formula:

CH181



in the (3aR, 7aR) and (3aRS, 7aRS) forms, and mixtures and salts thereof where

R represents hydrogen, or together R and R form a bond;

R' are identical and represent phenyl, optionally substituted by halogen or methyl in position 2 or 3;

X represents O, S or NR₃;

R₃ represents hydrogen, C₁₋₁₂alkyl (optionally substituted by one or more carboxy, dialkylamino, acylamino, alkoxycarbonyl, alkoxycarbonylamino, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl (where the alkyl portions of these radicals may contain a dialkylamino or phenyl substituent), phenyl (optionally substituted by halogen, alkyl, alkoxy or dialkylamino), naphthyl, thienyl, furyl, pyridyl or imidazolyl); or dialkylamino;

R₁ represents phenyl (optionally substituted by 1 or more halogen, OH, alkyl (optionally substituted by halogen, amino, alkylamino or dialkylamino), alkoxy or alkylthio (optionally substituted by OH or dialkylamino of which the alkyl portions may form a 5- to 6-membered heterocycle which can contain another O, S or N heteroatom), or substituted by amino, alkylamino or dialkylamino); or R₁ is a cyclohexadienyl, naphthyl or (un)saturated 5-9C mono or polycyclic heterocyclyl having one or more O, N or S heteroatoms;


R₂ represents H, halogen, OH, alkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, alkoxy, alkylthio, acyloxy, carboxy, alkoxycarbonyl, dialkylaminoalkoxycarbonyl, benzyloxycarbonyl, amino, acylamino or alkoxycarbonylamino; the various alkyl and acyl groups being straight or branched and of 1-4C atoms;

for example


CH181

- 6 -

CH181
styryl, 1
indan.
1-



EP 0428434 i.e. 1,4-diaralkylpiperidine and piperazine derivatives of the formula:



where

$m = 1-3$;

Ar, Ar¹ represents thienyl; phenyl optionally mono- or disubstituted by halogen, 1-3C alkyl, CF₃, 1-3C alkoxy, OH or methylenedioxy; or imidazolyl; or Ar¹ may also be benzothienyl optionally substituted by halogen; naphthyl optionally substituted by halogen; biphenyl; or indolyl optionally substituted by benzyl;

X¹ represents hydrogen or OH;

Y represents N or CX¹¹;

X and X¹¹ represent hydrogen; or X¹ or X¹¹ is a bond; or X and X¹ represent O or NO(CH₂)pAm;

p represents 2 or 3;

Am represents di(1-4Calkyl)amino;

Q represents hydrogen, 1-4Calkyl or (CH₂)qAm;

q represents 2 or 3;

Am represents piperidino, 4-benzylpiperidino or di(1-4Calkyl)amino;

R represents hydrogen, methyl or (CH₂)_nL;

L represents hydrogen or NH₂;

n represents 2-6;

T represents COM, COOM, CONHM or CSNHM;

M represents hydrogen, 1-6C alkyl, phenyl(1-3C)alkyl (optionally ring-substituted by halogen, OH, 1-4C alkoxy or 1-4C alkyl), pyridyl(1-3C)alkyl, naphthyl(1-3C)alkyl, pyridylthio(1-3C)alkyl,



2

•



1

 \mathbb{R}^2 \mathbb{R}^3 R^2

-C

 \mathbb{R}^4 R^5 R⁶

an






2

fo

CH181


- 8 -

CH181




EP 0394989 i.e. compounds of the formula

CH181



wherein R^1 is lower alkyl, aryl, arylamino, pyridyl, pyrrolyl, pyrazolopyridyl, quinolyl, or a group of the formula:



wherein the symbol of a line and dotted line is a single bond or double bond,

X is CH or N , and

Z is O , S or NH ,

each of which may have suitable substituents(s);

R^2 is hydrogen or lower alkyl;

R^3 is hydrogen or hydroxy;

R^4 is lower alkyl which may have suitable substituent(s), and

R^5 is ar(lower)alkyl which may have suitable substituent(s) or pyridyl(lower)alkyl, or

R^4 and R^5 are linked together to form benzene-condensed lower alkylene;

A is an amino acid residue excepting D-Trp, which may have suitable substituent(s); and


Y is a bond, lower alkylene or lower alkenylene;

for example


CH181

- 10 -


CH181



EP 0443132 i.e. compounds of the formula:



wherein R^1 is aryl, or a group of the formula:



wherein

X is CH or N, and

Z is O or N- R^5 , in which R^5 is hydrogen or lower alkyl,

R^2 is hydroxy or lower alkoxy,

R^3 is hydrogen lower alkyl which may have suitable substituent(s),


R^4 is ar(lower)alkyl which may have suitable substituent(s),

A is carbonyl or sulfonyl, and


Y is bond, or lower alkenylene;

for example

CH181



EP 0436334 i.e. compounds of the formula:



wherein Y is $(CH_2)_n$ wherein n is an integer from 1 to 4, and wherein any one of the carbon-carbon single bonds in said $(CH_2)_n$ may optionally be replaced by a carbon-carbon double bond, and wherein any one of the carbon atoms of said $(CH_2)_n$ may optionally be substituted with R^4 and wherein any one of the carbon atoms of said $(CH_2)_n$ may optionally be substituted with R^7 ;

Z is $(CH_2)_m$ wherein m is an integer from 0 to 6, and wherein any one of the carbon-carbon single bonds of $(CH_2)_m$ may optionally be replaced by a carbon-carbon double bond or carbon-carbon triple bond, and any one of the carbon atoms of said $(CH_2)_m$ may optionally be substituted with R^8 ;

R^1 is hydrogen or (C_1-C_8) alkyl optionally substituted with hydroxy, (C_1-C_4) alkoxy or fluoro;

R^2 is a radical selected from hydrogen, (C_1-C_6) straight or branched alkyl, (C_3-C_7) cycloalkyl wherein one of the CH_2 groups in said cycloalkyl may optionally be replaced by NH, oxygen or sulfur; aryl

CH181

selected from phenyl and naphthyl; heteroaryl selected from indanyl, thienyl, furyl, pyridyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, tetrazolyl and quinolyl; phenyl-(C₂-C₆)-alkyl, benzhydryl and benzyl, wherein each of said aryl, heteroaryl groups and the phenyl moieties of said benzyl, phenyl-(C₂-C₆)-alkyl and benzhydryl may optionally be substituted with one or more substituents independently selected from halo, nitro, (C₁-C₆) alkyl, (C₁-C₆) alkoxy, trifluoromethyl, amino, (C₁-C₆)-alkylamino, (C₁-C₆)alkyl-O-C(O)-, (C₁-C₆)alkyl-O-C(O)-(C₁-C₆)alkyl, (C₁-C₆)alkyl-C(O)-O-, (C₁-C₆)alkyl-C(O)-, (C₁-C₆)alkyl-O-, (C₁-C₆)alkyl-C(O)-, (C₁-C₆)alkyl-C(O)-(C₁-C₆)alkyl-, di-(C₁-C₆)alkylamino, -CONH-(C₁-C₆)alkyl, (C₁-C₆)-alkyl-CONH-(C₁-C₆)alkyl, NHC(O)H and -NHC(O)-(C₁-C₆) alkyl; and wherein one of the phenyl moieties of said benzhydryl may optionally be replaced by naphthyl, thienyl, furyl or pyridyl; R⁵ is hydrogen, phenyl or (C₁-C₆) alkyl; or R² and R⁵, together with the carbon to which they are attached, form a saturated ring having from 3 to 7 carbon atoms wherein one of the CH₂ groups in said ring may optionally be replaced by oxygen, NH or sulfur; R³ is aryl selected from phenyl and naphthyl; heteroaryl selected from indanyl, thienyl, furyl, pyridyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, tetrazolyl and quinolyl; and cycloalkyl having 3 to 7 carbon atoms wherein one of the (CH₂) groups in said cycloalkyl may optionally be replaced by NH, oxygen or sulfur; wherein each of said aryl and heteroaryl groups may optionally be substituted with one or more substituents, and said (C₃-C₇) cycloalkyl may optionally be substituted with one or two substituents, each of said substituents being independently selected from halo, nitro, (C₁-C₆) alkyl, (C₁-C₆) alkoxy, trifluoromethyl, amino, (C₁-C₆) alkylamino, -CONH-(C₁-C₆)alkyl, (C₁-C₆)alkyl-C(O)-NH-(C₁-C₆)alkyl, -NHC(O)H and -NHC(O)-(C₁-C₆)alkyl; and R⁴ and R⁷ are each independently selected from hydroxy, hydrogen, halo, amino, oxo, cyano, methylene, hydroxymethyl, halomethyl, (C₁-C₆)alkylamino, di-(C₁-C₆)alkylamino, (C₁-C₆) alkoxy,

CH181

(C₁-C₆)alkyl-O-C(O)-, (C₁-C₆)alkyl-O-C(O)-(C₁-C₆)alkyl, (C₁-C₆)alkyl-C(O), (C₁-C₆)alkyl-C(O)-(C₁-C₆)alkyl-O, (C₁-C₆)alkyl-C(O), (C₁-C₆)alkyl-C(O)-(C₁-C₆)alkyl-,

and the radicals set forth in the definition of R², R⁶ is NHC(O)R⁹, -NHCH₂R⁹, SO₂R⁹ or one of the radicals set forth in any of the definitions of R², R⁴ and R⁷;

R⁸ is oximino (=NOH) or one of the radicals set forth in any of the definitions of R², R⁴ and R⁷;

R⁹ is (C₁-C₆)alkyl, hydrogen, phenyl or phenyl(C₁-C₆)alkyl;

with the proviso that (a) when m is 0, R⁸ is absent, (b) when R⁴, R⁶, R⁷ or R⁸ is as defined in R², it cannot form, together with the carbon to which it is attached, a ring with R⁵, and (c) when R⁴ and R⁷ are attached to the same carbon atom, then either each of R⁴ and R⁷ is independently selected from hydrogen, fluoro and (C₁-C₆)alkyl, or R⁴ and R⁷, together with the carbon to which they are attached, form a (C₃-C₆) saturated carbocyclic ring that forms a spiro compound with the nitrogen-containing ring to which they are attached; and pharmaceutically acceptable acid addition salts thereof;

in particular cis-3-(2-methoxybenzylamino)-2-phenyl piperidine.

The tachykinin antagonists may be administered as the raw chemical but the active ingredients are preferably presented as a pharmaceutical formulation. Suitable pharmaceutical formulations are described in the above referenced patent specifications.

Suitable dose ranges are also described in the above referenced patent specifications, that is to say that for use as anti-emetics the compounds may be used at doses appropriate for other conditions for which tachykinin antagonists are known to be useful. It will be appreciated that it may be necessary to make routine variations to the dosage, depending on the age and condition of the patient, and the precise dosage will be ultimately at the discretion of the attendant physician or veterinarian. The dosage will also depend on the route of administration and the particular compound selected. A

CH181

suitable dose range is for example 0.1mg/kg to about 400mg bodyweight per day.

The tachykinin antagonists may, if desired, be administered in combination with one or more other therapeutic agents and formulated for administration by any convenient route in a conventional manner. Appropriate doses will be readily appreciated by those skilled in the art. For example, the tachykinin antagonists may be administered in combination with a systemic anti-inflammatory corticosteroid such as methyl prednisolone or dexamethasone, or a 5HT₃ antagonist such as ondansetron, granisetron or metoclopramide.

Biological Data

The anti-emetic activity of the test compound (\pm) cis-3-(2-methoxybenzylamino)-2-phenyl piperidine was demonstrated by its ability to inhibit cisplatin-induced emesis in the ferret.

In this model of emesis the onset of retching and vomiting occurs approximately 1 hour after the administration of cisplatin (200mg/m² i.p.). At the first retch in response to cisplatin, the test compound was administered (e.g. i.p., p.o., i.v., s.c., i.c.v.) and its effect on emesis determined by comparison with appropriate controls (e.g. water).

The test compound exhibited anti-emetic activity when administered at a dose of 3 mg/kg i.p.